Unity Biotechnology Inc
UBX
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.44M
Close$
$-0.95
574% downside
Current Fair Value
574% downsideOvervalued by 574% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.44 Million |
|---|---|
| Enterprise Value | $14.12 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.54 |
| Beta | 1.06 |
| Outstanding Shares | 16,870,800 |
Return
| Return on Equity | 13415.61% |
|---|---|
| Return on Assets | -90.63% |
| Return on Invested Capital | -176.26% |
Valuation & Multiples
| P/E Ratio | -0.21 |
|---|---|
| PEG | -0.82 |
| Price to Sales | - |
| Price to Book Ratio | -0.2 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.38 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 1.32 |
| Debt to Equity | -91.11 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
April 20, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Unity Biotechnology Inc
70 employees
CEO: Anirvan Ghosh UNITY is developing a new class of therapeutics to slow, halt or reverse diseases of aging. UNITY's current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases.